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Background: Hypomagnesaemia in patients with cystic fibrosis (CF) is underrecognized although the true incidence is unknown. Many
patients are asymptomatic, although severe deficiency may be associated with muscle weakness, cramps and tetany. Hypomagnesaemia may
be a risk factor for post-transplant complications including convulsions, which may be exacerbated by the use of calcineurin inhibitors. The
aims of the present study were to describe serum magnesium levels and to investigate the relationship between magnesium levels and age,
and renal function measurements in patients with CF referred to a transplant centre for lung transplant assessment.
Methods: We reviewed the data of all 106 CF patients referred for transplant assessment from January 1995 to December 2003. Demographic
and biochemical data were recorded and the explanatory variables were subjected to univariate analysis and linear regression analysis.
Results:Mean serum magnesium level was 0.75 mmol/L (range 0.46–1.03, normal range 0.74–1.1). 57% of patients had hypomagnesaemia.
Serum magnesium levels were not associated with age, serum creatinine or GFR.
Conclusions: Hypomagnesaemia is a common finding in patients with CF referred for lung transplant assessment. Serum magnesium levels
should be monitored in all CF patients being referred for lung transplant irrespective of the results of other renal function tests.
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The prognosis for cystic fibrosis (CF) patients has im-
proved significantly in recent years [1]. This has been achieved
as a result of increased understanding of the disease, the
establishment of specialised treatment centres and aggressive
management of complications. New problems are emerging as
the prognosis improves; some of these may be iatrogenic and
related to the requirement for aggressive medical therapy.
Hypomagnesaemia is increasingly recognised and appears to☆ The data was presented in poster form at the North American Cystic
Fibrosis Conference, St Louis, Missouri, USA, 2004, appearing subse-
quently in the Conference proceedings (Pediatr Pulmonol Suppl 2004;
volume 38; S27: 319).
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doi:10.1016/j.jcf.2007.01.004be mainly related to proximal renal tubular damage associated
with the use of frequent and prolonged courses of high dose
aminoglycoside antibiotics [2], although other factors includ-
ing malnutrition, malabsorption, secondary hyperaldosteron-
ism and diabetes mellitus may also be relevant.
The true incidence and the exact mechanism of hypomag-
nesaemia in CF are unknown. In this study we assess serum
magnesium levels in patients with CF referred to a transplant
centre for lung transplant assessment and investigate the
relationship between these levels and age, serum creatinine
and glomerular filtration rate (GFR).
2. Methods
The study was conducted in the regional cardio-thoracic
transplant unit at Freeman Hospital, Newcastle upon Tyne,
UnitedKingdomwhich is amajor supraregional lung transplant
centre for both adults and children. Patient information and
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assessment database at Freeman Hospital.
We reviewed the data of all CF patients referred for lung
transplant assessment from the transplant database from
January 1995 to December 2003. Demographic and bio-
chemical data included age, sex, serum magnesium levels,
serum creatinine (in micromol/L) and GFR (creatinine
clearance mL/min/1.73 m2).
3. Statistical analysis
Univariate analysis and linear regression was used to
describe associations between the explanatory variables (age,
creatinine and GFR) and the outcome variable (magnesium).
4. Results
A total of 106 patients were referred for lung transplant
assessment over an 8 year period. The median patient age
was 24.5 years (range 15.8–56.0 years). 59 (56%) were
male. Mean serum magnesium was 0.75±0.10 mmol/L
(mean±SD, range 0.46–1.03 mmol/L). 60 (57%) patients
were hypomagnesaemic (serum magnesiumb0.74 mmol/L).
Mean serum creatinine was 80.1±20.8 μmol/L (mean±SD,
range 50–226 μmol/L) and GFR 125.5±40.2 (22–227) mL/
min/1.73 m2. There was no statistically significant relation-
ship between serum magnesium levels and age (P value=
0.43, 95% confidence interval −0.015, 0.034, regression
coefficient 0.001). Similarly, there was no statistically sig
nificant relationship between serum magnesium and serum
creatinine levels (P value=0.47, 95% confidence interval
−0.001, 0.006, regression coefficient −0.0003) and GFR (P
value=0.60, 95% confidence interval −0.004, 0.001, regres
sion coefficient 0.001). Scatter plot of serum magnesium
levels against age is depicted in Fig. 1.
5. Discussion
Hypomagnesaemia is a common finding in patients with
CF referred for lung transplant assessment occurring in 57%of referrals. Serum magnesium levels were not associated
with age, serum creatinine or GFR. This is consistent with
renal physiology as a rising serum creatinine is a late marker
of renal dysfunction associated with impairment in GFR.
Magnesium homeostasis is controlled primarily by renal
mechanisms. The kidney filters the equivalent of 5% of the
total magnesium body store each day, but proximal tubular
resorption of 95% of filtered magnesium ordinarily main-
tains homeostasis [3].
For many years respiratory exacerbations of CF in child-
hood have been treated with intravenous aminoglycosides
administered up to three times a day. Even though safe blood
levels are defined for single courses of aminoglycoside,
repeated administrations are usually required. Concern has
been raised over the long term renal damage produced by
multiple exposures to intravenous aminoglycosides [2,4−6].
It was not possible in this study to document the cumulative
dose of aminoglycosides for each patient over the course of
their disease, but most patients will have received multiple
courses over many years. It is interesting that we did not find
a statistical relationship between serum magnesium and age,
as the progressive nature of CF is usually associated with
increasingly aggressive medical therapy and hence higher
cumulative doses of aminoglycosides as the patient ages.
High concentrations of aminoglycosides may accumulate
within the kidney, and damage the proximal tubular cells,
leading to prolonged tubular leak of magnesium. It is still
unclear whether aminoglycosides administered via nebuliser
produce adverse tubular effects. Although acute renal failure
has been reported with use of nebulised tobramycin [7]. It is
likely that the combination of intravenous and nebulised
aminoglycosides will have cumulative adverse effects [8,9].
There are several other reasons why CF patients may be
prone to hypomagnesaemia including CF related diabetes
mellitus, secondary hyperaldosteronism [11] and malabsorp-
tion. In patients with diabetes mellitus, the diuresis induced
by glycosuria results in increased urinary sodium and mag-
nesium losses [10]. Malabsorption can cause hypomagne-
saemia as this binds to fat and is lost in the stool and Booth
et al. [12] reported that faecal fat excretion correlated with
serum magnesium levels.
Calcineurin inhibitors such as cyclosporine A (CsA) and
tacrolimus (FK506) are widely prescribed in transplant reci-
pients and are known to produce hypomagnesaemia parti-
cularly with long term usage. The mechanism of this effect is
still unclear. Kim et al. [13] demonstrated that in mice these
immunosuppressants inhibit the hormone-stimulated magne-
sium uptake into the mouse distal convoluted tubule cells by
inhibiting the mitogen-activated protein kinase pathway.
Hypomagnesaemia is known to be a risk factor for neuro-
logical complications including seizures in lung transplant
recipients, which may be exacerbated by the use of calcineurin
inhibitors [14]. Hypomagnesaemia has also been reported as a
cause of severe cardiac arrhythmias in the immediate
postoperative period following renal transplant [15] and
during liver transplant surgery [16].
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may still have low levels post-transplant, so magnesium
levels still need to be monitored post-transplant irrespective
of pre-transplant levels. There is no evidence to support the
use of routine oral magnesium supplementation in CF pa-
tients with hypomagnesaemia.
In conclusion, hypomagnesaemia is a common finding
amongst patients with CF referred for lung transplant assess-
ment. This finding appears to be independent of age and other
parameters of renal function (creatinine and GFR). This
supports the recommendation to measure magnesium levels
in patients referred for lung transplant assessment, even if
creatinine and GFR are normal. Further work is required to
investigate the relationship between hypomagnesaemia and
post operative morbidity in lung transplant patients.
References
[1] Cystic Fibrosis Foundation. National cystic fibrosis patient registry
annual data report, 2004. Bethesda, MD: Cystic Fibrosis Foundation;
2005.
[2] Aminoglycoside-associated hypomagnesaemia in children with cystic
fibrosis. Acta Paediatr 1999;88:783–5.
[3] Magnesium deficiency in cystic fibrosis. South Med J 1983;76:1586.
[4] Kaloyanides GJ. Drug–phospholipid interactions: role in aminoglyco-
side nephrotoxicity. Ren Fail 1992;14:351–7.
[5] Glass S, Plant ND, Spencer DA. The effects of intravenous tobramycin
on renal tubular function in children with cystic fibrosis. J Cyst Fibros
Dec 2005;4(4):221–5.[6] Kaloyanides GJ. Aminogycoside nephrotoxicity. In: Schrier R, Gotts-
chalk C, editors. Diseases of the kidney. 5th ed. Boston: Little, Brown
and Co.; 1992. p. 1131–63.
[7] Hoffmann IM, Rubin BK, Iskandar SS, Schechter MS, Nagaraj SK,
Bitzan MM. Acute renal failure in cystic fibrosis: association with
inhaled tobramycin therapy. Pediatr Pulmonol 2002;34:375–7.
[8] Tan KH, Mulheran M, Knox AJ, Smyth AR. Aminoglycoside pres-
cribing and surveillance in cystic fibrosis. Am J Respir Crit Care Med
2003;167:819–23.
[9] Bloomer J, Sharpe CA, Sewell A, Spencer DA. Monitoring amino-
glycoside levels in paediatric patients receiving once daily intravenous
therapy. Pediatr Pulmonol 2005;40(S28):288.
[10] MartinHE.Clinical magnesiumdeficiency. AnnNYAcad Sci 1969;162:
891–900.
[11] Simopoulas AP, Lapey A, Boat TF. The rennin–angiotensin–
aldosterone system in patients with cystic fibrosis of the pancreas.
Pediatr Res 1971;5:626.
[12] Booth CC, Babouris N, Hanna S, MacIntyre I. Incidence of hypo-
magnesaemia in intestinal malabsorption. Br Med J 1963;2:141–4.
[13] Kim SJ, Kang HS, Jeong CW, Park SY, Kim IS, Kim NS, et al.
Immunosuppressants inhibit hormone stimulated Mg2+ uptake in
mouse distal convoluted tubule cells. Biochem Biophys Res Commun
2006;341(3):742–8.
[14] Goldstein LS, Haug MT, Perl J, Perl MK, Maurer JR, Arroliga AC,
et al. Central nervous system complications after lung transplanta-
tion. J Heart Lung Transplant 1998;17(2): 185–91.
[15] Mohsin N, Jha A, Al Maimani Y, Malvathu R, Kallankara S. Hypo-
magnesaemia as a cause of severe cardiac arrythmias in the immediate
postoperative period: a renal transplant case report. Transplant Proc
2003;35:2652.
[16] Ranasinghe DN,Mallett SV. Hypomagnesaemia, cardiac arrhythmias and
orthotopic liver transplantation. Anaesthesia May 1994;49(5): 403–5.
